Antidepressants Don’t Impact Stimulants’ Efficacy in ADHDLast Updated: August 16, 2011. In adults with attention deficit hyperactivity disorder, concomitant use of antidepressants does not affect the safety or efficacy of osmotic release oral system methylphenidate, according to a study published online Aug. 5 in CNS Neuroscience & Therapeutics.
TUESDAY, Aug. 16 (HealthDay News) -- In adults with attention deficit hyperactivity disorder (ADHD), concomitant use of antidepressants does not affect the safety or efficacy of osmotic release oral system methylphenidate (OROS-MPH), according to a study published online Aug. 5 in CNS Neuroscience & Therapeutics.
Joseph Biederman, M.D., from Massachusetts General Hospital in Boston, and colleagues examined whether the response to OROS-MPH was moderated by the concomitant use of antidepressants in adults with ADHD. A total of 223 patients with anxiety disorders and depression were analyzed, including 109 in the OROS-MPH group and 114 in the placebo group. Patients treated with a stable medication regimen of non-monoamine oxidase inhibitor antidepressants or benzodiazepines for at least three months were enrolled. Patients were required to have Hamilton-Depression and Hamilton-Anxiety scales below 15 (mild range) at the time they were enrolled.
The investigators found no association between concomitant antidepressant use at baseline and ADHD response, OROS-MPH dose, study completion rate, adverse effects, or worsening of anxiety or depression. There was nominally significant evidence of a lifetime history of mood or anxiety disorders being a moderator of ADHD symptoms. A potential moderator of dose at end point was a lifetime history of substance use disorder.
"We found few moderating effects in this large clinical trial of OROS-MPH in adults with ADHD, which supports the robustness of the clinical response to OROS-MPH in adult ADHD despite variable clinical pictures," the authors write.
All of the study authors disclosed financial relationships with the pharmaceutical and health care industry, including Ortho-McNeil Janssen Scientific Affairs, which provided financial support for the study.